Twitter

Chordate Medical presents Ozilia® at Finnish Neurology Congress

Chordate Medical is currently in Helsinki to present the migraine treatment Ozilia® at the Finnish Neurology Association’s congress, taking place from November 1st to 3rd. The congress is gathering 450 delegates from across Finland.

“We are met with significant interest from numerous migraine specialists and neurologists. The Ozilia® treatment is considered a necessary and welcome drug-free addition to the treatment arsenal. The Finnish clinics that participated in the migraine study PM007 are a big asset and help in spreading awareness of Ozilia® in the country,” says Anders Weilandt, CEO of Chordate Medical.

Ozilia® is a CE-marked nerve-stimulating treatment method that offers a drug-free alternative for chronic migraine. The treatment has clinically proven efficacy according to a recent study, and is marketed in Finland, Germany, the UK, Italy, Israel, and Saudi Arabia.

More posts

Press releases

If you want to read our press releases, there are available in the Investor Relations section or by clicking the link below.

Press releases

For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of Ozilia® Migraine, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

Contact us

  • This field is for validation purposes and should be left unchanged.

The information is handled according to our privacy policy

Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine (formerly K.O.S), a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). 

The company’s Certified Adviser on Nasdaq First North Growth Market Stockholm is Vator Securities AB.

Press releases

Chordate Medical AB

c/o Regus, Kistagången 20B
SE-164 40 Kista
Sweden

Privacy policy

Twitter